Anne-Renee Hartman
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, DNA Repair Mechanisms, BRCA gene mutations in cancer, Genetic factors in colorectal cancer, PARP inhibition in cancer therapy
Most-Cited Works
- → TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer(2015)426 cited
- → BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study(2014)292 cited
- → Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105(2015)226 cited
- → Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway(2006)209 cited
- → Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history(2017)147 cited
- → Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer(2017)131 cited
- → Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort(2016)114 cited
- → Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)(2015)71 cited
- → Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015(2020)71 cited
- → Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma(2014)45 cited